IP Library Granted Patent US 10,421,942
Granted Patent B2
US 10,421,942 · App. 15/431,634 · Granted Sep 24, 2019

Definitive endoderm

Inventors: Kevin Allen D'Amour (San Diego, CA); Alan D. Agulnick (San Diego, CA); Emmanuel E. Baetge (Encinitas, CA)
Assignee: ViaCyte, Inc.
C12N5/0606C12N5/0603C12N5/068C12N2501/15C12N2501/155C12N2501/16C12N2501/415C12N2502/13C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,421,942
App. No.
15/431,634
Granted
Sep 24, 2019
Kind
B2
Abstract

Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.

Claims (12)

1. An in vitro method of producing human definitive endoderm cells that express SRY-box 17 (SOX17) and hepatocyte nuclear factor-3 beta (HNF3β), the method comprising:

(a) culturing a population of human pluripotent stem cells; and

(b) differentiating the population of human pluripotent stem cells by culturing said population in a culture medium comprising equal to or less than 2%V/V serum and at least 30 ng/ml of activin A for a time sufficient to cause differentiation of said human pluripotent stem cells into human definitive endoderm cells expressing SOX17 and HNF3β, thereby generating the human definitive endoderm cells expressing SOX17 and HNF3β in said population.

2. The method of claim 1 wherein the culture medium further comprises:

(a) hone morphogenetic protein-4 (BMP4) in an amount sufficient to promote differentiation of the population of human pluripotent stem cells to definitive endoderm cells; or

(b) activin B in an amount sufficient to promote differentiation of the human pluripotent stem cells to definitive endoderm cells.

3. The method of claim 1 , wherein activin A in the culture medium is at a concentration of about 30 ng/ml-500 ng/ml.

4. The method of claim 2 , wherein activin B in the culture medium is at a concentration of about 10 ng/ml-500 ng/ml.

5. The method of claim 2 , wherein BMP4 in the culture medium is at a concentration of about 10 ng/ml-500 ng/ml of BMP4.

6. The method of claim 1 , wherein the culture medium further comprises a WNT protein in an amount sufficient to promote differentiation of the population of human pluripotent stern cells to definitive endoderm cells.

7. The method of claim 6 , wherein the WNT protein in Wnt3A.

8. The method of claim 1 , wherein the population comprising definitive endoderm cells is substantially free of cells derived from the ectoderm lineage.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2017
From: D'AMOUR, KEVIN ALLEN; AGULNICK, ALAN D.; BAETGE, EMMANUEL E.
To: CYTHERA, INC.
Reel/Frame 042661/0353 →
CHANGE OF NAME Recorded Jun 9, 2017
From: CYTHERA, INC.
To: VIACYTE, INC.
Reel/Frame 042755/0500 →
Continuity (7)
Continuation 14702642 · Nov 5, 2013
Continuation 12710300 · Feb 22, 2010
Continuation 10584338
Provisional Application 60587942 · Jul 14, 2004
Provisional Application 60586566 · Jul 9, 2004
Provisional Application 60532004 · Dec 23, 2003
Related Publication 20170159011A1 · Jun 8, 2017